Sep 12, 2022 / 04:30PM GMT
Michael Eric Ulz - Morgan Stanley, Research Division - Equity Analyst
All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here, and it's my pleasure to introduce the team from Karyopharm Therapeutics, including Richard Paulson, CEO, on my far left; and Reshma Rangwala, CMO, on my near left.
Just a reminder, the format for today is a fireside chat. But before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. And with that, we can start the Q&A.
Questions and Answers:
Michael Eric Ulz - Morgan Stanley, Research Division - Equity AnalystSo I thought maybe, obviously, XPOVIO is an important part of the story here. It's been on
Trustpilot
